



New Day in Medicine
Новый День в Медицине

NDM



TIBBIYOTDA YANGI KUN

Ilmiy referativ, marifiy-ma'naviy jurnal



AVICENNA-MED.UZ



ISSN 2181-712X.
EiSSN 2181-2187

5 (79) 2025

Сопредседатели редакционной коллегии:

**Ш. Ж. ТЕШАЕВ,
А. Ш. РЕВИШВИЛИ**

Ред. коллегия:

М.И. АБДУЛЛАЕВ
А.А. АБДУМАЖИДОВ
Р.Б. АБДУЛЛАЕВ
Л.М. АБДУЛЛАЕВА
А.Ш. АБДУМАЖИДОВ
М.А. АБДУЛЛАЕВА
Х.А. АБДУМАДЖИДОВ
Б.З. АБДУСАМАТОВ
М.М. АКБАРОВ
Х.А. АКИЛОВ
М.М. АЛИЕВ
С.Ж. АМИНОВ
Ш.Э. АМОНОВ
Ш.М. АХМЕДОВ
Ю.М. АХМЕДОВ
С.М. АХМЕДОВА
Т.А. АСКАРОВ
М.А. АРТИКОВА
Ж.Б. БЕКНАЗАРОВ (главный редактор)
Е.А. БЕРДИЕВ
Б.Т. БУЗРУКОВ
Р.К. ДАДАБАЕВА
М.Н. ДАМИНОВА
К.А. ДЕХКОНОВ
Э.С. ДЖУМАБАЕВ
А.А. ДЖАЛИЛОВ
Н.Н. ЗОЛотова
А.Ш. ИНОЯТОВ
С. ИНДАМИНОВ
А.И. ИСКАНДАРОВ
А.С. ИЛЪЯСОВ
Э.Э. КОБИЛОВ
А.М. МАННАНОВ
Д.М. МУСАЕВА
Т.С. МУСАЕВ
М.Р. МИРЗОЕВА
Ф.Г. НАЗИРОВ
Н.А. НУРАЛИЕВА
Ф.С. ОРИПОВ
Б.Т. РАХИМОВ
Х.А. РАСУЛОВ
Ш.И. РУЗИЕВ
С.А. РУЗИБОЕВ
С.А. ГАФФОРОВ
С.Т. ШАТМАНОВ (Кыргызстан)
Ж.Б. САТТАРОВ
Б.Б. САФОЕВ (отв. редактор)
И.А. САТИВАЛДИЕВА
Ш.Т. САЛИМОВ
Д.И. ТУКСАНОВА
М.М. ТАДЖИЕВ
А.Ж. ХАМРАЕВ
Д.А. ХАСАНОВА
Б.З. ХАМДАМОВ
А.М. ШАМСИЕВ
А.К. ШАДМАНОВ
Н.Ж. ЭРМАТОВ
Б.Б. ЕРГАШЕВ
Н.Ш. ЕРГАШЕВ
И.Р. ЮЛДАШЕВ
Д.Х. ЮЛДАШЕВА
А.С. ЮСУПОВ
Ш.Ш. ЯРИКУЛОВ
М.Ш. ХАКИМОВ
Д.О. ИВАНОВ (Россия)
К.А. ЕГЕЗАРЯН (Россия)
DONG JINCHENG (Китай)
КУЗАКОВ В.Е. (Россия)
Я. МЕЙЕРНИК (Словакия)
В.А. МИТИШ (Россия)
В.И. ПРИМАКОВ (Беларусь)
О.В. ПЕШИКОВ (Россия)
А.А. ПОТАПОВ (Россия)
А.А. ТЕПЛОВ (Россия)
Т.Ш. ШАРМАНОВ (Казахстан)
А.А. ЩЕГОЛОВ (Россия)
С.Н. ГУСЕЙНОВА (Азербайджан)
Prof. Dr. KURBANHAN MUSLUMOV (Azerbaijan)
Prof. Dr. DENIZ UYAK (Germany)

ТИББИЁТДА ЯНГИ КУН НОВЫЙ ДЕНЬ В МЕДИЦИНЕ NEW DAY IN MEDICINE

*Илмий-рефератив, маънавий-маърифий журнал
Научно-реферативный,
духовно-просветительский журнал*

УЧРЕДИТЕЛИ:

**БУХАРСКИЙ ГОСУДАРСТВЕННЫЙ
МЕДИЦИНСКИЙ ИНСТИТУТ
ООО «ТИББИЁТДА ЯНГИ КУН»**

Национальный медицинский
исследовательский центр хирургии имени
А.В. Вишневского является генеральным
научно-практическим
консультантом редакции

Журнал был включен в список журнальных
изданий, рецензируемых Высшей
Аттестационной Комиссией
Республики Узбекистан
(Протокол № 201/03 от 30.12.2013 г.)

РЕДАКЦИОННЫЙ СОВЕТ:

М.М. АБДУРАХМАНОВ (Бухара)
Г.Ж. ЖАРЫЛКАСЫНОВА (Бухара)
А.Ш. ИНОЯТОВ (Ташкент)
Г.А. ИХТИЁРОВА (Бухара)
Ш.И. КАРИМОВ (Ташкент)
У.К. КАЮМОВ (Тошкент)
Ш.И. НАВРУЗОВА (Бухара)
А.А. НОСИРОВ (Ташкент)
А.Р. ОБЛОКУЛОВ (Бухара)
Б.Т. ОДИЛОВА (Ташкент)
Ш.Т. УРАКОВ (Бухара)

5 (79)

2025

май

www.bsmi.uz

<https://newdaymedicine.com> E:

ndmuz@mail.ru

Тел: +99890 8061882

Received: 20.04.2025, Accepted: 06.05.2025, Published: 10.05.2025

UDK 616.33

COMORBID STATUS IN PATIENTS WITH GASTRIC ULCER AND DUODENAL ULCER

Juraeva Khafiza Iskandarovna <https://orcid.org/0000-0001-6992-5464> E-mail:
xafiza_jurayeva@bsmi.uz

Abduraxmonova Fazilat Akbar qizi <http://orcid.org/0009-0009-7080-4681>

Bukhara State Medical Institute named after Abu Ali ibn Sina, Uzbekistan, Bukhara, st. A. Navoi.

1 Tel: +998 (65) 223-00-50 e-mail: info@bsmi.uz

✓ Resume

The article presents data on the structure and frequency of comorbid diseases in patients with gastric ulcer and duodenal ulcer. The study included 67 patients who were hospitalized. The comorbid status of patients was assessed based on the Charlson index. Comorbid conditions were detected in 97% of patients. In 2/3 of patients, there was a combination of several comorbid diseases. When choosing therapy, it is necessary to take into account the existing comorbidity, the presence of which affects the course of the disease, reduces the effectiveness of the treatment, and increases the frequency of hospitalizations.

Key words: gastric ulcer and duodenal ulcer, comorbidity, concomitant pathology

КОМОРБИДНЫЙ СТАТУС У БОЛЬНЫХ ЯЗВЕННОЙ БОЛЕЗНЬЮ ЖЕЛУДКА И ДВЕНАДЦАТИПЕРСТНОЙ КИШКИ

Жураева Х.И. <https://orcid.org/0000-0001-6992-5464> E-mail: xafiza_jurayeva@bsmi.uz

Абдурахмонова Ф.А. <http://orcid.org/0009-0009-7080-4681>

Бухарский государственный медицинский институт имени Абу Али ибн Сины, Узбекистан,
г. Бухара, ул. А. Навои. 1 Тел: +998 (65) 223-00-50 e-mail: info@bsmi.uz

✓ Резюме

В статье представлены данные по структуре и частоте коморбидных заболеваний у больных язвенной болезнью желудка и двенадцатиперстной кишки. В исследование включены 67 больных, находившихся на стационарном лечении. Оценка коморбидного статуса пациентов проведена на основании определения индекса Чарлсона. Коморбидные состояния выявлялись у 97 % больных. У 2/3 пациентов имело место сочетание нескольких коморбидных заболеваний. При выборе терапии необходимо учитывать имеющуюся коморбидность, наличие которой влияет на течение заболевания, снижает эффективность проводимого лечения, увеличивает частоту госпитализаций.

Ключевые слова: язвенная болезнь желудка и двенадцатиперстной кишки, коморбидность, сопутствующая патология.

OSHQOZON VA O'N IKKI BARMOQLI ICHAK YARASI BOR BEMORLARDA KOMORBID STATUS

Juraeva Khafiza Iskandarovna <https://orcid.org/0000-0001-6992-5464> E-mail:
xafiza_jurayeva@bsmi.uz

Abduraxmonova Fazilat Akbar qizi <http://orcid.org/0009-0009-7080-4681>

Abu Ali ibn Sino nomidagi Buxoro davlat tibbiyot instituti, O'zbekiston, Buxoro sh. A. Navoiy
kochasi 1 Tel: +998 (65) 223-00-50 e-mail: info@bsmi.uz

✓ **Rezyume**

Maqolada oshqozon yarasi va o'n ikki barmoqli ichak yarasi bo'lgan bemorlarda komorbid kasalliklarning tuzilishi va chastotasi haqida ma'lumotlar keltirilgan. Tadqiqotda statsionar davolanayotgan 67 bemor ishtirok etdi. Bemorlarning komorbid holatini baholash Charlson indeksi asosida amalga oshirildi. Bemorlarning 97 % da komorbid holatlar aniqlangan. Bemorlarning 2/3 qismida bir nechta komorbid kasalliklarning kombinatsiyasi mavjud. Terapiyani tanlashda mavjud bo'lgan komorbidlikni hisobga olish kerak, uning mavjudligi kasallikning kechishiga ta'sir qiladi, davolash samaradorligini pasaytiradi va kasalxonaga yotqizish chastotasini oshiradi.

Kalit so'zlar: oshqozon va o'n ikki barmoqli ichak yarasi, yondosh kasalliklar, komorbidlik

Relevance

The relevance of the problem under consideration is determined by the high frequency and prevalence of peptic ulcer disease (PUD), which continues to this day, its often long course with the possible formation of frequently recurring and difficult-to-heal ulcers, as well as the risk of developing serious complications. Moreover, concomitant comorbid conditions are one of the leading causes of a significant deterioration in the quality of life of patients with this pathology with an increased risk of adverse outcomes, including fatal ones [1–7]. The relevance of this study is due to the negative impact of prognostically significant comorbidity in PU on the quality of life and survival of patients, as well as the lack to date of a comprehensive assessment of the main clinically significant variants of comorbid pathology on the course of the disease, as well as the choice and determination of treatment tactics [8–9].

The aim of the study was to investigate the frequency and structure of comorbid diseases in patients with gastric ulcer (GU) and duodenal ulcer (DU) who were undergoing inpatient treatment.

The aim of the study was to investigate the frequency and structure of comorbid diseases in patients with gastric ulcer (GU) and duodenal ulcer (DU) who were undergoing inpatient treatment.

Materials and methods of the study

The study group included 67 patients with GU and DU. Among them, 14 (21%) were women and 53 (79%) were men. The average age of patients was 54.7 ± 7.9 years. Among the examined patients, 70% of cases were diagnosed with GU and 30% of cases were diagnosed with DU. 75% of patients were infected with *Helicobacter (H.) pylori*. The average duration of ulcer history was 11.2 ± 5.9 years. At the time of the study, all patients were receiving standard antiulcer therapy. During the study, an analysis of the medical records of patients who were undergoing inpatient treatment at the regional multidisciplinary medical center in Navai was conducted, the selection of which was carried out by random sampling. The medical history of each patient was used to determine age, height, weight, social status, occupational status, duration of ulcer disease, presence of a family history of ulcer disease, concomitant pathology, complete blood count, biochemical blood test results, *H. pylori* infection, and esophagogastroduodenoscopy data. Based on the results of anthropometric parameters, the body mass index (BMI) was calculated in order to clarify the degree of obesity and its impact on the comorbid status of patients and the effectiveness of treatment for PU. The study determined the Charlson index for quantitative assessment of comorbid status and 10-year survival of patients.

Statistical analysis of the obtained data was performed using the Microsoft Office XP and Excel statistical software package, including calculations of arithmetic means (M), errors of arithmetic means (m), and an assessment of the reliability of differences between groups using Student's t-test (at $p < 0.05$, the differences were considered reliable). Correlation dependence was assessed using the r criterion. Calculations were performed on a 1600 MHz "Intel Pentium-IV" CPU.

Results and discussion

The study showed that concomitant pathology was detected in 97% of patients with PU (Fig. 1). The structure of comorbidity in the analyzed group of patients was represented mainly by cardiovascular pathology, which was observed in 85% of patients.

The most frequently recorded diseases were arterial hypertension (in 75% of patients) and ischemic heart disease (in 47%); myocardial dystrophy was less common – in 32% of patients. 38% of patients had normal weight, 27% had pre-obesity, 17% had grade 1 obesity, 12% had grade 2 obesity, and 6%

had grade 3 obesity. Along with cardiovascular pathology, there was a high incidence of gastrointestinal tract (GIT) diseases in patients with ulcerative colitis (PU) – in 79% of patients. The most frequently recorded diseases were chronic cholecystitis – 32%, chronic gastritis – 27%, steatohepatitis – 18% and chronic pancreatitis – 20%. Chronic inflammatory diseases of the urinary tract were diagnosed in 37% of patients with ulcerative colitis.




Fig. 1. Concomitant diseases in patients with ulcerative colitis

Among joint diseases, osteoarthritis was detected in 27% of patients with ulcerative colitis, mainly in patients over 45 years of age. Osteochondrosis of the spine was diagnosed in 16% of patients. Endocrine pathology was detected in 22% of patients (Fig. 2): 18% had type 2 diabetes mellitus, 7% had thyroid pathology. Respiratory pathology was observed relatively rarely and was represented by bronchial asthma in 3% of cases, and chronic obstructive pulmonary disease in 10%.




Fig. 2. Comorbidity structure in patients with peptic ulcer disease

Malignant neoplasms were diagnosed in 2% of patients and had different localizations. When assessing the Charlson index, 10-year survival rates over 90% (index values from 0 to 2 points) were noted in 28% of patients, from 53 to 77% (index values 3–4) – in 52% and less than 21% (≥ 5 points) – in 20%. Conducting a correlation analysis showed that the Charlson comorbidity index has a direct positive correlation with age, duration of the history of ulcer disease and body mass index (Table 1).

Table 1

Correlation dependence of the CHARLSON index in patients with PU

Indicators	Index CHARLSON
Age	0,7
Duration of history of PU	0,6
Body mass index	0,7

Conclusion

Thus, the conducted study revealed a high prevalence of comorbid diseases in patients with PU. It is important to note that 2/3 of patients have a combination of several comorbid diseases. This creates additional difficulties in selecting therapy, is often the cause of polypharmacy and increases the risk of adverse reactions. In clinical practice, in patients with PU, it is necessary to take into account the existing comorbidity, the presence of which affects the course of the disease, reduces the effectiveness of the therapy, and increases the frequency of hospitalizations. Evaluation of comorbidity is an important component of clinical prognosis in order to take timely measures to correct treatment and prevent disease progression.

LIST OF REFERENCES:

1. Ширинская Н. В. Язвенная болезнь желудка и двенадцатиперстной кишки в Российской Федерации. Заболеваемость и смертность // Дальневосточный медицинский журнал. – 2016. – № 3. – С. 105–109.
2. Ивашкин В. Т., Лапина Т. Л. Гастроэнтерология. Национальное руководство. – М.: ГЭОТАР-Медиа, 2015. – 480 с.
3. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению язвенной болезни / В. Т. Ивашкин, А. А. Шептулин, И. В. Маев [и др.] // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2016. – № 6. – С. 40–54.
4. Полозова Э. И., Трохина И. Е., Куркина Н. В., Горшенина Е. И. Оценка эффективности применения комбинированной терапии в комплексном лечении язвенной болезни двенадцатиперстной кишки [Электронный ресурс] // Современные проблемы науки и образования. – 2017. – № 3. – URL: <http://www.scienceeducation.ru/article/view?id%20=26519>.
5. Полозова Э. И., Трохина И. Е. Пути повышения эффективности лечения язвенной болезни желудка и двенадцатиперстной кишки // Научное обозрение. Медицинские науки. – 2018. – № 2. – С. 24–28.
6. Жураева Хафиза Искандаровна, Мажидова Мехрибан Ахмедовна, & Яхяева Хилола Шарифовна (2018). Анализ оценки отношения к состоянию своего здоровья среди неорганизованного населения. // Биология и интегративная медицина, (3), 118-128..
7. O'Connor A., Molina-Infante J., Gisler J. P., O'Morain C. Treatment of Helicobacter pylori infection 2013 // Helicobacter. – 2013. – Vol. 18. – P. 58–65.
8. Khafiza, J., Dildora, T. (2023). Frequency of Comorbid Pathology among Non-Organized Population. // Research Journal of Trauma and Disability Studies, 2(4), 260-266.
9. Кац Я. А., Пархонюк Е. В., Труфанова Ю. Ю., Скрипцова С. А. Проблема единого подхода к коморбидности [Электронный ресурс] // Современные проблемы науки и образования. – 2016. – № 3. – URL: <http://scienceeducation.ru/ru/article/view?id=24541>.

Entered 20.04.2025